You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: May 22, 2025

CLINICAL TRIALS PROFILE FOR ASCORBIC ACID


✉ Email this page to a colleague

« Back to Dashboard


505(b)(2) Clinical Trials for Ascorbic Acid

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
New Dosage NCT01533090 ↗ Evaluation of Reduced-volume PEG Bowel Preparation Administered the Same Day of Colonoscopy Completed Catholic University of the Sacred Heart N/A 2010-04-01 The conventional total dose of 4 L of polyethylene glycol (PEG) given the day before the procedure is safe and effective. It has been the standard cleansing regimen for the last 25 years. To overcome the difficulty in completing the bowel preparation due to large volume and/or taste, reduced-volume (mixed) bowel preparation of bisacodyl and 2 L of PEG have been shown to provide adequate colon cleansing and better tolerability. LoVol-esse is a reduced-volume PEG-based bowel preparation to be used in combination with bisacodyl and designed to improve patient tolerability and attitude toward bowel cleansing prior to colonoscopy thanks to the reduced volume and improved taste. The present study is intended to compare the new dosing regimen of the bowel lavage solution given the same day compared with standard PEG formulation (SELG 1000) given the day before colonoscopy.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Ascorbic Acid

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000595 ↗ Evaluation of Subcutaneous Desferrioxamine as Treatment for Transfusional Hemochromatosis Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 2 1978-01-01 To determine whether deferoxamine prevented the complications of transfusional iron overload.
NCT00006021 ↗ Arsenic Trioxide Plus Vitamin C in Treating Patients With Recurrent or Refractory Multiple Myeloma Completed National Cancer Institute (NCI) Phase 1/Phase 2 2000-06-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Vitamin C may increase the effectiveness of arsenic trioxide by making cancer cells more sensitive to the drug. PURPOSE: Phase I/II trial to determine the effectiveness of arsenic trioxide plus vitamin C in treating patients who have recurrent or refractory multiple myeloma.
NCT00006021 ↗ Arsenic Trioxide Plus Vitamin C in Treating Patients With Recurrent or Refractory Multiple Myeloma Completed University of Miami Phase 1/Phase 2 2000-06-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Vitamin C may increase the effectiveness of arsenic trioxide by making cancer cells more sensitive to the drug. PURPOSE: Phase I/II trial to determine the effectiveness of arsenic trioxide plus vitamin C in treating patients who have recurrent or refractory multiple myeloma.
NCT00085345 ↗ Melphalan, Arsenic Trioxide, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma Withdrawn Oncotherapeutics Phase 2 1969-12-31 RATIONALE: Drugs used in chemotherapy, such as melphalan, arsenic trioxide, and ascorbic acid, work in different ways to stop cancer cells from dividing so they stop growing or die. Arsenic trioxide and ascorbic acid may also help melphalan kill more cancer cells by making them more sensitive to the drugs. PURPOSE: This phase II trial is studying how well giving melphalan together with arsenic trioxide and ascorbic acid works in treating patients with relapsed or refractory multiple myeloma.
NCT00102271 ↗ Nitrite Infusion Studies Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 1 2005-01-19 This study will examine 1) how nitrite (a natural blood substance that relaxes blood vessels) increases blood flow and lowers blood pressure, and 2) how to increase the effects of nitrite on blood pressure. Healthy volunteers between 21 and 40 years of age may be eligible for this study. They must be non-smokers and have no history of high blood pressure, high cholesterol, or diabetes. Candidates are screened with a medical history, physical examination, electrocardiogram, and blood tests. This study is either done in the NIH Clinical Center intensive care unit or on the general clinical ward. Participants are enrolled in Part A of the study. After completion of Part A participants will be enrolled in Part B of the study. Part A: Participants lie in a reclining chair during the study. Small catheters (plastic tubes) are inserted into an artery and vein in the forearm. Another tube is placed in the vein of the opposite arm. Blood pressure cuffs are placed around the upper arm and wrist, and a strain gauge (a rubber band-like device) is placed around the forearm. This device helps us to measure blood flow through the arm. When the blood pressure cuffs are inflated, blood flows into the forearm, stretching the strain gauge at a rate proportional to the blood flow. Pressure cuffs and a strain gauge are also placed on the other arm. After 20 minutes, blood pressure and blood flow are measured in both forearms. Then blood is drawn from the tube in the right vein to measure blood counts, proteins, and other chemicals. Participants then are given small doses of either saline, ascorbic acid, or a medicine called oxypurinol, a form of a drug that is often taken to prevent gout. After 30 minutes, sodium nitrite is injected in increasing doses into the artery for 30 minutes. Blood flow is measured and blood is drawn every 5 minutes during the infusion. At the end of the 30 minutes, blood is drawn from the vein every 30 minutes for 3 hours. After 3 hours, sodium nitrite infusions are restarted for 2 hours and blood flow is measured and samples collected every 30 minutes during this period. Part B: Participants lie in a reclining chair during the study. A small catheter (plastic tube) is placed in the artery of the left forearm to draw blood samples. A larger catheter called a central line is placed in a deeper vein in the neck. Another tube is advanced through the central line into the chambers of the heart, through the heart valve, and into the lung artery to measure pressures in the heart and lungs. Blood is drawn after 30 minutes to obtain baseline measurements. Then saline (sterile salt water) is put into the tube in the lung artery. Blood pressure cuffs are placed around the upper arm and wrist, and a strain gauge (a rubber band-like device) is placed around the forearm, which helps us to measure flow through the arm. When the cuffs are inflated, blood flows into the forearm, stretching the strain gauge at a rate proportional to the blood flow. Pressure cuffs and a strain gauge are also placed on the other arm. After 20 minutes, blood pressure and blood flow are measured in the forearm and blood samples are drawn from the tube in the left artery to measure blood counts, proteins, and other chemicals. Subjects then breathe a mixture of oxygen and nitrogen through a facemask for 30 minutes, then room air for 30 minutes, and then the oxygen and nitrogen mixture for another 30 minutes. While breathing the mixture the second time, sodium nitrite is injected through the tube in the artery in three increasing doses for 5 minutes each. Every 5 minutes during the infusion blood is drawn from the tubes in the neck. Forearm blood flow is also measured every 5 minutes. After 30 minutes, the subject breathes room air for 3 hours and 15 minutes and then the sodium nitrite is injected again in three increasing doses for 5 minutes each. Every 5 minutes during the infusion blood is taken from the tube in the neck and forearm blood flow is measured
NCT00112879 ↗ Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma Withdrawn The Cleveland Clinic Phase 2 1969-12-31 RATIONALE: Drugs used in chemotherapy, such as arsenic trioxide and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Thalidomide may stop the growth of multiple myeloma by blocking blood flow to the cancer. Giving arsenic trioxide together with ascorbic acid, dexamethasone, and thalidomide may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving arsenic trioxide together with ascorbic acid, dexamethasone, and thalidomide work in treating patients with multiple myeloma.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Ascorbic Acid

Condition Name

Condition Name for Ascorbic Acid
Intervention Trials
Sepsis 10
Septic Shock 9
Colonoscopy 7
Pancreatic Cancer 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Ascorbic Acid
Intervention Trials
Multiple Myeloma 13
Pancreatic Neoplasms 12
Neoplasms, Plasma Cell 11
Sepsis 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Ascorbic Acid

Trials by Country

Trials by Country for Ascorbic Acid
Location Trials
United States 132
Korea, Republic of 22
Spain 12
Egypt 8
Italy 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Ascorbic Acid
Location Trials
Pennsylvania 12
New York 10
California 10
Arizona 8
Massachusetts 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Ascorbic Acid

Clinical Trial Phase

Clinical Trial Phase for Ascorbic Acid
Clinical Trial Phase Trials
Phase 4 34
Phase 3 30
Phase 2/Phase 3 7
[disabled in preview] 93
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Ascorbic Acid
Clinical Trial Phase Trials
Completed 105
Recruiting 25
Unknown status 24
[disabled in preview] 44
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Ascorbic Acid

Sponsor Name

Sponsor Name for Ascorbic Acid
Sponsor Trials
National Cancer Institute (NCI) 13
Thomas Jefferson University 7
Cephalon 5
[disabled in preview] 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Ascorbic Acid
Sponsor Trials
Other 316
Industry 39
NIH 21
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Ascorbic Acid: Clinical Trials, Market Analysis, and Projections

Introduction

Ascorbic acid, commonly known as vitamin C, has been a subject of intense research and market interest due to its versatile applications in healthcare, food, and cosmetics. This article delves into the latest clinical trials, market analysis, and projections for ascorbic acid.

Clinical Trials: Recent Findings and Implications

COVID-19 Treatment

A randomized clinical trial published in 2022 investigated the use of pharmacologic ascorbic acid as an early therapy for hospitalized patients with COVID-19. The study found that patients receiving ascorbic acid in addition to standard care showed a higher rate of clinical improvement within 72 hours compared to those receiving standard care alone, although the difference was not statistically significant. Notably, the ascorbic acid group had a lower incidence of fever and a higher discharge rate[1].

Cancer Treatment

High-dose intravenous (IV) vitamin C has shown promising results in cancer treatment. A phase 2 clinical trial at the University of Iowa demonstrated that adding high-dose IV vitamin C to chemotherapy doubled the overall survival of patients with advanced pancreatic cancer. Similar positive outcomes were observed in trials involving patients with glioblastoma and non-small cell lung cancer. These studies highlight the potential of IV vitamin C in enhancing the efficacy of chemotherapy and radiation therapies[4].

Market Analysis

Current Market Size and Growth

The global ascorbic acid market is experiencing significant growth. As of 2025, the market size is estimated to be around USD 2.08 billion, with a projected growth to USD 2.74 billion by 2030 at a CAGR of 5.66%[2].

Regional Market Dynamics

The Asia Pacific region currently holds the largest market share, while Europe is expected to be the fastest-growing region over the forecast period. This growth is driven by increasing demand for ascorbic acid in food, beverages, and cosmetic products[2].

Product Segments

The market is segmented into various product forms, including granules, liquid, and powder. The sodium ascorbate segment is anticipated to account for the largest revenue share due to its widespread use as an antioxidant in food products and its potential in cancer therapy[3].

Application Segments

The food and beverage sector dominates the application segment, driven by the use of ascorbic acid as a preservative and antioxidant. The personal care and cosmetics segment also shows significant growth, particularly in anti-aging products[3].

Market Projections

Forecasted Growth

By 2030, the ascorbic acid market is projected to reach USD 3.90 billion at a CAGR of 7.59%, according to some forecasts. This growth is attributed to increasing use in dietary supplements, intravenous administration for chronic conditions, and rising demand in the cosmetics industry[5].

Key Drivers

Several factors are driving the market growth:

  • Increasing Use in Food and Beverages: Ascorbic acid is used to preserve freshness and color in food products.
  • Rising Demand in Cosmetics: Anti-aging serums and creams containing vitamin C are gaining popularity.
  • Clinical Trials and Research: Ongoing research on the anti-cancer and cytotoxic activities of ascorbic acid is boosting its medical applications[3].

Major Players

The ascorbic acid market is characterized by the presence of several major players, including:

  • Merck KGaA
  • Foodchem International Corporation
  • Koninklijke DSM NV
  • Northeast Pharmaceutical Group Co. Ltd
  • Shandong Luwei Pharmaceutical Co Ltd[2].

Conclusion

Ascorbic acid is a multifaceted compound with expanding applications in healthcare, food, and cosmetics. Clinical trials have highlighted its potential in treating COVID-19 and various types of cancer. The market is poised for significant growth, driven by increasing demand in multiple sectors and ongoing research that underscores its therapeutic benefits.

Key Takeaways

  • Ascorbic acid shows promise in treating COVID-19 and certain types of cancer.
  • The global ascorbic acid market is expected to grow significantly, reaching USD 2.74 billion by 2030.
  • The Asia Pacific region holds the largest market share, with Europe being the fastest-growing region.
  • Sodium ascorbate and food-grade ascorbic acid are key segments driving market growth.
  • Major players include Merck KGaA, Foodchem International Corporation, and Koninklijke DSM NV.

FAQs

What is the current market size of the ascorbic acid market?

The ascorbic acid market size is estimated to reach USD 2.08 billion in 2025[2].

Which region is expected to grow the fastest in the ascorbic acid market?

Europe is estimated to be the fastest-growing region over the forecast period[2].

What are the primary applications of ascorbic acid?

Ascorbic acid is primarily used in the food and beverage sector as a preservative and antioxidant, and in the personal care and cosmetics sector, particularly in anti-aging products[3].

Which product segment is expected to account for the largest revenue share?

The sodium ascorbate segment is expected to account for the largest revenue share due to its growing use in food products and potential in cancer therapy[3].

What is the projected CAGR for the ascorbic acid market from 2025 to 2030?

The ascorbic acid market is projected to grow at a CAGR of 7.59% from 2025 to 2030[5].

Sources

  1. Coppock, D.; Violet, P.-C.; Vasquez, G.; et al. Pharmacologic Ascorbic Acid as Early Therapy for Hospitalized Patients with COVID-19: A Randomized Clinical Trial. Life 2022, 12, 453. https://doi.org/10.3390/life12030453
  2. Mordor Intelligence. Vitamin C (Ascorbic Acid) Market Size & Share Analysis. https://www.mordorintelligence.com/industry-reports/ascorbic-acid-market
  3. Reports and Data. Ascorbic Acid Market Size to Reach USD 1.61 Billion in 2028, Says Reports and Data. https://www.biospace.com/ascorbic-acid-market-size-to-reach-usd-1-61-billion-in-2028-says-reports-and-data
  4. University of Iowa. High-dose IV vitamin C plus chemotherapy doubles survival in advanced pancreatic cancer. https://medicine.uiowa.edu/content/high-dose-iv-vitamin-c-plus-chemotherapy-doubles-survival-advanced-pancreatic-cancer
  5. 360iResearch. Ascorbic Acid Market Size & Share 2025-2030. https://www.360iresearch.com/library/intelligence/ascorbic-acid
Last updated: 2025-01-01

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.